Sergio Salmerón Ríos1, Marta Mas Romero2, Elisa Belén Cortés Zamora2, María Teresa Tabernero Sahuquillo2, Luis Romero Rizos2,3,4, Pedro Manuel Sánchez-Jurado2,3,4, Ginés Sánchez-Nievas5, José Joaquín Blas Señalada6, Inmaculada García Nogueras1, Juan de Dios Estrella Cazalla2,3,7, Fernando Andrés-Pretel8, Antonio Murillo Romero9, Volker Martin Lauschke10, Justin Stebbing11, Pedro Abizanda2,3,4. 1. Residencia de Mayores San Vicente de Paúl, Diputación de Albacete, Albacete, Spain. 2. Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 3. CIBERFES, Ministerio de Economía y Competitividad, Spain. 4. Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. 5. Department of Rheumatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 6. Department of Microbiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 7. Diputación de Albacete, Vasco Núñez de Balboa Facility, Albacete, Spain. 8. Department of Statistics, Foundation of the National Paraplegics Hospital of Toledo, Toledo, Spain. 9. Long-Term Care Facilities Coordination, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 10. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. 11. Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, ICTEM building, London, United Kingdom.
Abstract
BACKGROUND/ OBJECTIVES: The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older adults across frailty and disability profiles. DESIGN: Multicenter longitudinal cohort study. SETTING AND PARTICIPANTS: A total of 134 residents aged ≥65 years with different frailty and disability profiles in five long-term care facilities (LTCFs) in Albacete, Spain. INTERVENTION AND MEASUREMENTS: Residents were administered two vaccine doses as per the label, and antibody levels were determined 21.9 days (SD 9.3) after both the first and second dose. Functional variables were assessed using activities of daily living (Barthel Index), and frailty status was determined with the FRAIL instrument. Cognitive status and comorbidity were also evaluated. RESULTS: Mean age was 82.9 years (range 65-99), and 71.6% were female. The mean antibody titers in residents with and without previous COVID-19 infection were 49,878 AU/ml and 15,274 AU/ml, respectively (mean difference 34,604; 95% confidence interval [CI]: 27,699-41,509). No severe adverse reactions were observed, after either vaccine dose. Those with prevaccination COVID-19 had an increased antibody level after the vaccine (B = 31,337; 95% CI: 22,725-39,950; p < 0.001). Frailty, disability, older age, sex, cognitive impairment, or comorbidities were not associated with different antibody titers. CONCLUSIONS: The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine.
BACKGROUND/ OBJECTIVES: The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older adults across frailty and disability profiles. DESIGN: Multicenter longitudinal cohort study. SETTING AND PARTICIPANTS: A total of 134 residents aged ≥65 years with different frailty and disability profiles in five long-term care facilities (LTCFs) in Albacete, Spain. INTERVENTION AND MEASUREMENTS: Residents were administered two vaccine doses as per the label, and antibody levels were determined 21.9 days (SD 9.3) after both the first and second dose. Functional variables were assessed using activities of daily living (Barthel Index), and frailty status was determined with the FRAIL instrument. Cognitive status and comorbidity were also evaluated. RESULTS: Mean age was 82.9 years (range 65-99), and 71.6% were female. The mean antibody titers in residents with and without previous COVID-19infection were 49,878 AU/ml and 15,274 AU/ml, respectively (mean difference 34,604; 95% confidence interval [CI]: 27,699-41,509). No severe adverse reactions were observed, after either vaccine dose. Those with prevaccination COVID-19 had an increased antibody level after the vaccine (B = 31,337; 95% CI: 22,725-39,950; p < 0.001). Frailty, disability, older age, sex, cognitive impairment, or comorbidities were not associated with different antibody titers. CONCLUSIONS: The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine.
Authors: Adam H Dyer; Claire Noonan; Matt McElheron; Isabella Batten; Conor Reddy; Emma Connolly; Rachel Pierpoint; Caroline Murray; Ann Leonard; Catriona Higgins; Phyllis Reilly; Gerard Boran; Thomas Phelan; William McCormack; Desmond O'Neill; Aoife Fallon; Gareth Brady; Cliona O'Farrelly; Nollaig M Bourke; Sean P Kennelly Journal: J Am Med Dir Assoc Date: 2022-01-11 Impact factor: 7.802
Authors: Estela Giménez; Juan Alberola; Ignacio Torres; Eliseo Albert; María Jesús Alcaraz; Pilar Botija; Paula Amat; María José Remigia; María José Beltrán; Celia Rodado; Dixie Huntley; Beatriz Olea; David Navarro Journal: J Infect Date: 2021-11-02 Impact factor: 6.072
Authors: Gian Luca Salvagno; Brandon M Henry; Giovanni di Piazza; Laura Pighi; Simone De Nitto; Damiano Bragantini; Gian Luca Gianfilippi; Giuseppe Lippi Journal: Diagnostics (Basel) Date: 2021-05-04